List of Excipients in Branded Drug ALOGLIPTIN AND PIOGLITAZONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN AND PIOGLITAZONE	alogliptin benzoate and pioglitazone hydrochloride	45802-238	ALCOHOL	2029-06-04
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN AND PIOGLITAZONE	alogliptin benzoate and pioglitazone hydrochloride	45802-238	BUTYL ALCOHOL	2029-06-04
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN AND PIOGLITAZONE	alogliptin benzoate and pioglitazone hydrochloride	45802-238	CARNAUBA WAX	2029-06-04
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN AND PIOGLITAZONE	alogliptin benzoate and pioglitazone hydrochloride	45802-238	CELLULOSE, MICROCRYSTALLINE	2029-06-04

Alogliptin and Pioglitazone Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Alogliptin/pioglitazone is a fixed-dose oral combination of a DPP-4 inhibitor and a thiazolidinedione, marketed in the United States as Oseni. The product is a conventional immediate-release, film-coated tablet available in four strengths: 25/15 mg, 25/30 mg, 25/45 mg, and 12.5/15 mg of alogliptin benzoate and pioglitazone hydrochloride, respectively. Its principal commercial opportunity is a lower-cost generic or regional branded alternative supported by manufacturing efficiency, supply reliability, and differentiated packaging rather than a novel excipient platform.

The product has no biosimilar pathway because both active ingredients are synthetic small molecules. Regulatory and intellectual-property exposure centers on abbreviated new drug applications, formulation and process patents, Orange Book listings, paragraph IV certifications, and market demand for oral type 2 diabetes therapies.

What is alogliptin/pioglitazone and how is it used?

Alogliptin/pioglitazone combines complementary mechanisms for glycemic control:

Component	Drug class	Primary mechanism	Typical fixed-dose strengths
Alogliptin benzoate	DPP-4 inhibitor	Inhibits DPP-4, increasing incretin activity	12.5 mg or 25 mg
Pioglitazone hydrochloride	Thiazolidinedione	Activates PPAR-gamma and improves insulin sensitivity	15 mg, 30 mg, or 45 mg

The FDA approved Oseni in January 2013 as an adjunct to diet and exercise for adults with type 2 diabetes inadequately controlled on pioglitazone alone or requiring additional glycemic control. It is not indicated for type 1 diabetes or diabetic ketoacidosis. The label carries important warnings concerning congestive heart failure, edema, weight gain, bladder cancer risk, fractures, hypoglycemia when used with insulin or insulin secretagogues, and acute pancreatitis.[1]

Alogliptin is generally dose-adjusted in renal impairment. Pioglitazone does not require renal dose adjustment but has fluid-retention and cardiovascular safety considerations. These differences create a formulation and labeling requirement: the combination must preserve dose accuracy for both actives while supporting multiple strength ratios.

What excipients are used in alogliptin/pioglitazone tablets?

The U.S. prescribing information identifies a conventional tablet platform. The core uses mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate. The film coating uses hypromellose, titanium dioxide, and colorants, including iron oxide pigments depending on strength.[1]

Formulation function	Excipient or excipient class	Commercial role
Diluent	Mannitol	Provides bulk and supports tablet mouthfeel
Dry binder and filler	Microcrystalline cellulose	Improves compactibility and mechanical strength
Superdisintegrant	Croscarmellose sodium	Promotes rapid tablet breakup
Binder	Povidone	Improves granule or powder cohesion
Lubricant	Magnesium stearate	Reduces ejection force and tooling friction
Film former	Hypromellose	Provides protective and cosmetic coating
Opacifier	Titanium dioxide	Controls opacity and appearance
Colorant	Iron oxides	Differentiates dose strengths

This is a relatively accessible excipient system. It does not depend on a proprietary controlled-release polymer, lipid carrier, amorphous solid dispersion, enteric coating, or specialized capsule technology. That reduces technical barriers for generic development.

What is the likely manufacturing process?

The formulation is compatible with direct compression or a granulation-based process, depending on the selected API particle properties and target tablet weight. A commercial developer would normally evaluate:

1. API particle-size distribution and flow.
2. Blend uniformity across two active ingredients with different dose levels.
3. Segregation risk caused by differences in density and particle size.
4. Magnesium stearate mixing time and its effect on dissolution.
5. Compression force, friability, and tablet hardness.
6. Film-coating weight gain and color uniformity.
7. Stability under high humidity and elevated temperature.

The 12.5/15 mg strength creates the greatest low-dose content-uniformity challenge because alogliptin represents a smaller mass fraction of the tablet. A robust strategy would use controlled API particle engineering, ordered mixing, geometric dilution, or wet granulation rather than relying only on extended blending.

What excipient strategy is best for generic development?

The lowest-risk strategy is to replicate the functional performance of the reference product with widely accepted compendial excipients. A generic developer does not need to duplicate the brand’s excipient suppliers or manufacturing equipment, but it must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.[2]

Core formulation strategy

Mannitol and microcrystalline cellulose are commercially attractive because they support both flow and compression. Croscarmellose sodium provides a familiar disintegration mechanism without creating modified-release behavior. Povidone gives flexibility if the developer uses wet granulation.

The main formulation variables are:

Development issue	Preferred control strategy
Low-dose alogliptin uniformity	Narrow API particle-size distribution and staged blending
Pioglitazone hydrophobicity	Controlled wetting, adequate disintegrant distribution, and dissolution screening
Over-lubrication	Defined magnesium stearate concentration and mixing endpoint
Tablet weight	Keep sufficient mass for content uniformity without creating an oversized tablet
Strength differentiation	Use coating color and imprinting rather than major core changes
Stability	Control moisture, packaging permeability, and API-excipient compatibility
Scale-up	Use a process that remains robust across batch-size changes

A replacement excipient system can be commercially viable if it produces equivalent dissolution and bioavailability. Potential substitutions include lactose or dibasic calcium phosphate for mannitol, crospovidone or sodium starch glycolate for croscarmellose sodium, and hydroxypropyl cellulose or pregelatinized starch for povidone. Each substitution increases formulation and regulatory work.

Which excipients create the best commercial differentiation?

The strongest near-term opportunity is not a new pharmacological effect. It is improved manufacturing economics.

Potential differentiators include:

• Lower-cost direct-compression grades.
• Co-processed mannitol-cellulose systems.
• Lower coating weight with equivalent appearance and protection.
• Magnesium stearate alternatives that reduce dissolution variability.
• Low-moisture excipient systems for tropical markets.
• Smaller tablets through higher-density fillers.
• Alcohol-free, aqueous film-coating systems.
• Packaging optimized for moisture protection without excessive cost.
• Color systems that simplify global registration.

A developer should avoid unnecessary excipient innovation. A new superdisintegrant, novel binder, or noncompendial coating polymer could create additional extractables, toxicology, and regulatory requirements without producing a strong market advantage.

What formulation patents protect alogliptin/pioglitazone?

The relevant intellectual-property categories include:

1. Combination-product patents covering alogliptin and pioglitazone in specified ratios.
2. Composition-of-matter patents covering alogliptin or its benzoate salt.
3. Pioglitazone composition-of-matter and formulation patents.
4. Method-of-use patents covering treatment of type 2 diabetes.
5. Manufacturing or crystalline-form patents involving an active ingredient or salt.
6. Regulatory exclusivity and pediatric exclusivity.

The commercial impact depends on the current U.S. Orange Book listing, patent expiration dates, terminal disclaimers, pediatric extensions, and any approved generic certifications. FDA’s Orange Book identifies patents submitted by sponsors for approved drug products, but it does not establish patent validity or enforceability.[3]

A generic developer should separate two questions:

• Whether the proposed product is pharmaceutically equivalent and bioequivalent.
• Whether the proposed product can be marketed before all relevant patents expire.

An excipient substitution generally does not avoid a patent that claims the active ingredients, a fixed-dose combination, or a treatment method. It can help avoid a narrow formulation patent that claims a specific excipient, ratio, coating, manufacturing step, or dissolution profile.

When does alogliptin/pioglitazone lose exclusivity?

The product’s regulatory and patent exclusivity must be analyzed separately.

Exclusivity category	Relevance to alogliptin/pioglitazone
New chemical entity exclusivity	Applies to qualifying active ingredients, not necessarily the later fixed-dose combination
New combination exclusivity	May protect the approved combination for a defined period
Pediatric exclusivity	Can add six months if FDA requirements are satisfied
Patent exclusivity	Depends on issued claims, expiration, extensions, and litigation
Generic approval	May occur after expiration or successful challenge of blocking patents

The combination was approved in 2013, so the original regulatory exclusivity period is no longer the primary barrier in the United States. The practical entry question is the remaining patent estate and whether FDA has approved any ANDA products.

Because patent status changes through expiration, disclaimer, litigation, and Orange Book corrections, a launch assessment should use the current Orange Book and relevant USPTO records rather than relying on the original approval date.[3,4]

What is the Orange Book status of Oseni?

Oseni is an FDA-approved prescription drug and is associated with an NDA held by Takeda Pharmaceuticals U.S.A. The Orange Book is the controlling FDA source for approved products, therapeutic-equivalence evaluations, and listed patents.[3]

The commercial diligence file should capture:

• NDA number and product status.
• Approved strengths.
• Listed patents and expiration dates.
• Pediatric exclusivity, if any.
• Therapeutic-equivalence codes for approved ANDA products.
• Whether each strength has an active generic competitor.
• Any patent-use-code limitations affecting method-of-use certifications.

A developer should not assume that absence of a currently marketed generic means that no ANDA has been approved. Approved products may be discontinued, temporarily unavailable, or marketed only in selected channels.

Are there paragraph IV challenges to alogliptin/pioglitazone?

A paragraph IV certification is an ANDA applicant’s position that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. A first-filer paragraph IV applicant can obtain 180 days of generic exclusivity if statutory conditions are met.[5]

For alogliptin/pioglitazone, paragraph IV exposure is most likely to involve:

• Combination patents.
• Salt or crystalline-form claims.
• Narrow formulation claims.
• Method-of-use claims.
• Patents listed for one or more strengths rather than the entire product family.

A paragraph IV filing can trigger patent litigation within the Hatch-Waxman 45-day period and may create a 30-month FDA approval stay, subject to statutory exceptions.[5] The economic value of a challenge is lower when the reference product has limited sales, multiple generic filers are present, or the remaining patent term is short.

Publicly accessible sources should be reviewed for current Abbreviated New Drug Application litigation involving Oseni, alogliptin, pioglitazone, and relevant patent numbers. No biosimilar litigation framework applies.

What manufacturing and IP barriers affect generic entry?

The manufacturing barrier is moderate. Both active ingredients are established oral small molecules, and the reference formulation uses common excipients. The principal technical barriers are blend uniformity, dissolution reproducibility, and stability rather than novel drug delivery.

The IP barrier can be higher than the formulation barrier if a surviving patent claims:

• The combination at a defined dose ratio.
• A particular alogliptin salt or polymorph.
• A specific formulation architecture.
• A manufacturing process that is difficult to design around.
• A treatment method that creates certification or labeling issues.

A generic applicant can consider a “carve-out” label for a patented method of use if the remaining indication can be marketed lawfully. This approach requires careful analysis of FDA labeling, patent-use codes, promotional materials, and induced-infringement risk.

How does alogliptin/pioglitazone compare with competing diabetes combinations?

Product or class	Commercial position	Excipient and IP implications
Alogliptin/pioglitazone	Oral DPP-4/PPAR-gamma combination	Conventional immediate-release tablet; generic manufacturing is accessible
Sitagliptin/metformin	High-recognition DPP-4/metformin combination	Larger installed base and substantial generic competition
Linagliptin/metformin	DPP-4/metformin combination	Stronger contemporary commercial relevance in many markets
Saxagliptin/metformin	DPP-4/metformin combination	Modified-release options create greater process complexity
Pioglitazone/metformin	Low-cost insulin-sensitizer combination	Established generic competition and price pressure
GLP-1 receptor agonists	Injectable or oral incretin therapies	Higher clinical differentiation and more complex device or formulation IP
SGLT2 inhibitor combinations	Oral combination products	Stronger growth profile but more active patent and regulatory estates

The primary competitive disadvantage is pioglitazone’s safety and tolerability profile. Weight gain, edema, heart-failure warnings, and fracture risk limit prescribing relative to newer classes. DPP-4 inhibitors also face competition from GLP-1 receptor agonists and SGLT2 inhibitors, which have broader cardiometabolic positioning in some treatment guidelines.

What commercial opportunities exist for excipient suppliers and generic manufacturers?

Generic pharmaceutical opportunity

A generic manufacturer can pursue a conventional immediate-release tablet with:

• Four dosage strengths.
• Shared tooling across strengths.
• Common excipient platform.
• Strength-specific film-coat colors.
• High-volume bottle packaging.
• Blister packaging for markets with adherence or humidity concerns.

The most attractive opportunity is likely regional or institutional supply rather than premium U.S. branded competition. Price, continuity of supply, and regulatory registration will matter more than novel formulation claims.

Excipient supplier opportunity

Excipient suppliers can target:

• Direct-compression mannitol grades.
• Co-processed fillers with improved flow.
• Low-peroxide povidone grades.
• Consistent croscarmellose sodium grades.
• Lubricant systems that minimize dissolution impact.
• Film-coating premixes for dose-strength differentiation.
• Moisture-barrier packaging components.

A supplier with documented compatibility, compaction, and dissolution data can reduce development time for generic applicants. The strongest sales proposition is process robustness across multiple strengths, not a new therapeutic claim.

Licensing opportunity

Licensing may be relevant for:

• Regional rights to alogliptin/pioglitazone tablets.
• Authorized generic supply.
• Contract manufacturing of selected strengths.
• Private-label distribution.
• Technology transfer for high-throughput tablet production.
• Combination-product registrations outside the United States.

The limited growth profile of the underlying therapy reduces the likelihood of a high-value global licensing deal. Small or mid-sized markets with restricted access to newer diabetes drugs may offer more practical opportunities than the United States.

What is the revenue exposure for originator and generic entrants?

The originator’s revenue exposure is determined by current U.S. sales, payer coverage, generic availability, and the continuing role of pioglitazone in treatment guidelines. Public company disclosures do not generally isolate Oseni revenue from broader product portfolios. A precise revenue estimate cannot be derived from the FDA label or Orange Book alone.

For a generic entrant, the principal commercial risks are:

• Low total market demand.
• Multiple approved or pending generic competitors.
• Reimbursement-driven price compression.
• Limited prescriber preference for the combination.
• Strength-specific inventory requirements.
• Substitution by metformin, SGLT2, GLP-1, or insulin therapies.

A launch is more defensible when the applicant has an existing diabetes sales channel, manufacturing scale, or access to markets where pioglitazone remains widely used.

What is the overall patent strength of alogliptin/pioglitazone?

The patent estate should be rated as moderate to weak from a long-term commercial perspective, subject to the current Orange Book record. The formulation itself uses ordinary excipients and does not create a major technology barrier. The more important risks are active-ingredient, combination, salt, method-of-use, and remaining patent-term issues.

Risk area	Indicative assessment
Excipient patent barrier	Low
Tablet manufacturing barrier	Low to moderate
Bioequivalence risk	Moderate
Low-dose uniformity risk	Moderate
Combination patent risk	Product-specific and potentially material
Method-of-use risk	Moderate, depending on patent-use codes
Biosimilar risk	None
Commercial demand risk	Moderate to high
Geographic opportunity	Higher in selected cost-sensitive markets

Key Takeaways

• Alogliptin/pioglitazone is a conventional immediate-release, film-coated tablet marketed as Oseni.
• The core excipients are mannitol, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate, with a hypromellose-based film coating.
• Generic development is technically feasible without specialized delivery technology.
• The main formulation risks are low-dose alogliptin uniformity, dissolution control, lubrication, and stability.
• Excipient substitution can help design around narrow formulation claims but will not avoid active-ingredient or combination patents.
• No biosimilar pathway applies; Hatch-Waxman ANDA and paragraph IV analysis control U.S. generic entry.
• Commercial potential is stronger for cost-efficient regional supply and institutional procurement than for premium U.S. market positioning.
• The current Orange Book, USPTO records, FDA exclusivity data, and litigation docket must control any launch-date or patent-expiration conclusion.

FAQs

Can alogliptin/pioglitazone be formulated as an extended-release tablet?

Yes, but an extended-release product would be a distinct formulation strategy with new dissolution, bioequivalence, stability, and labeling requirements. It would not automatically qualify as an equivalent to the immediate-release Oseni product.

Which excipient is most important for alogliptin content uniformity?

The critical factor is usually the blending and particle-engineering system rather than one excipient. Microcrystalline cellulose and mannitol provide the main diluent platform, while controlled API particle size and geometric dilution reduce segregation risk.

Is lactose a practical substitute for mannitol?

Yes, lactose can be evaluated as a filler, but it changes compaction, moisture behavior, density, and potential API compatibility. Comparative dissolution and stability testing would be required.

Does pioglitazone’s boxed-warning status prevent generic combination development?

No. Safety warnings do not prevent ANDA development. The generic must meet FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing quality, and applicable patent certifications.

Could a smaller tablet create a meaningful commercial advantage?

Yes. A smaller tablet can improve swallowability, packaging efficiency, and patient acceptance. The benefit must be achieved without compromising dose uniformity, hardness, disintegration, dissolution, or manufacturability.

References

1. U.S. Food and Drug Administration. (2023). Oseni (alogliptin and pioglitazone) prescribing information. Takeda Pharmaceuticals U.S.A., Inc.

2. U.S. Food and Drug Administration. (2024). ANDAs for certain highly purified synthetic peptides: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2024). The Hatch-Waxman Amendments: Questions and answers on 30-month stays and paragraph IV certifications. FDA.